Logo image of EYPT

EYEPOINT PHARMACEUTICALS INC (EYPT) Stock Fundamental Analysis

NASDAQ:EYPT - Nasdaq - US30233G2093 - Common Stock - Currency: USD

7.8  +0.18 (+2.36%)

After market: 7.77 -0.03 (-0.38%)

Fundamental Rating

4

Overall EYPT gets a fundamental rating of 4 out of 10. We evaluated EYPT against 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for EYPT as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, EYPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

EYPT had negative earnings in the past year.
EYPT had a negative operating cash flow in the past year.
In the past 5 years EYPT always reported negative net income.
In the past 5 years EYPT reported 4 times negative operating cash flow.
EYPT Yearly Net Income VS EBIT VS OCF VS FCFEYPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.42%, EYPT is in line with its industry, outperforming 51.61% of the companies in the same industry.
EYPT's Return On Equity of -47.35% is in line compared to the rest of the industry. EYPT outperforms 58.60% of its industry peers.
Industry RankSector Rank
ROA -34.42%
ROE -47.35%
ROIC N/A
ROA(3y)-32.93%
ROA(5y)-45.22%
ROE(3y)-54.78%
ROE(5y)-218.78%
ROIC(3y)N/A
ROIC(5y)N/A
EYPT Yearly ROA, ROE, ROICEYPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

1.3 Margins

EYPT has a better Gross Margin (91.48%) than 95.16% of its industry peers.
EYPT's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for EYPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.68%
GM growth 5YN/A
EYPT Yearly Profit, Operating, Gross MarginsEYPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

EYPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EYPT has more shares outstanding
EYPT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EYPT Yearly Shares OutstandingEYPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
EYPT Yearly Total Debt VS Total AssetsEYPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

EYPT has an Altman-Z score of -0.34. This is a bad value and indicates that EYPT is not financially healthy and even has some risk of bankruptcy.
EYPT has a Altman-Z score (-0.34) which is comparable to the rest of the industry.
EYPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.34
ROIC/WACCN/A
WACC9.57%
EYPT Yearly LT Debt VS Equity VS FCFEYPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

EYPT has a Current Ratio of 5.50. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.50, EYPT is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
A Quick Ratio of 5.45 indicates that EYPT has no problem at all paying its short term obligations.
EYPT's Quick ratio of 5.45 is fine compared to the rest of the industry. EYPT outperforms 69.35% of its industry peers.
Industry RankSector Rank
Current Ratio 5.5
Quick Ratio 5.45
EYPT Yearly Current Assets VS Current LiabilitesEYPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

EYPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.81%, which is quite impressive.
Looking at the last year, EYPT shows a small growth in Revenue. The Revenue has grown by 7.51% in the last year.
The Revenue has been growing by 73.11% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)24.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.64%
Revenue 1Y (TTM)7.51%
Revenue growth 3Y10.14%
Revenue growth 5Y73.11%
Sales Q2Q%-30.77%

3.2 Future

Based on estimates for the next years, EYPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.35% on average per year.
The Revenue is expected to grow by 45.97% on average over the next years. This is a very strong growth
EPS Next Y-26.2%
EPS Next 2Y-20.3%
EPS Next 3Y-17.61%
EPS Next 5Y19.35%
Revenue Next Year6.2%
Revenue Next 2Y-33.32%
Revenue Next 3Y-40.27%
Revenue Next 5Y45.97%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EYPT Yearly Revenue VS EstimatesEYPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
EYPT Yearly EPS VS EstimatesEYPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EYPT. In the last year negative earnings were reported.
Also next year EYPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EYPT Price Earnings VS Forward Price EarningsEYPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EYPT Per share dataEYPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A cheap valuation may be justified as EYPT's earnings are expected to decrease with -17.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.3%
EPS Next 3Y-17.61%

More info and screens

0

5. Dividend

5.1 Amount

EYPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EYEPOINT PHARMACEUTICALS INC

NASDAQ:EYPT (2/5/2025, 8:00:01 PM)

After market: 7.77 -0.03 (-0.38%)

7.8

+0.18 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-28 2024-10-28/bmo
Earnings (Next)02-27 2025-02-27/amc
Inst Owners109.28%
Inst Owner Change0.41%
Ins Owners1.14%
Ins Owner Change0.41%
Market Cap531.18M
Analysts84.44
Price Target33.66 (331.54%)
Short Float %16.3%
Short Ratio12.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.71%
Min EPS beat(2)-8.31%
Max EPS beat(2)4.9%
EPS beat(4)2
Avg EPS beat(4)0.1%
Min EPS beat(4)-29.62%
Max EPS beat(4)33.44%
EPS beat(8)4
Avg EPS beat(8)-28.67%
EPS beat(12)7
Avg EPS beat(12)-16.57%
EPS beat(16)8
Avg EPS beat(16)-43.19%
Revenue beat(2)1
Avg Revenue beat(2)-0.37%
Min Revenue beat(2)-3.15%
Max Revenue beat(2)2.41%
Revenue beat(4)3
Avg Revenue beat(4)17.11%
Min Revenue beat(4)-3.15%
Max Revenue beat(4)54.46%
Revenue beat(8)5
Avg Revenue beat(8)10.54%
Revenue beat(12)7
Avg Revenue beat(12)7.37%
Revenue beat(16)7
Avg Revenue beat(16)0.01%
PT rev (1m)0%
PT rev (3m)-7.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.94%
EPS NY rev (1m)0%
EPS NY rev (3m)4.22%
Revenue NQ rev (1m)4.83%
Revenue NQ rev (3m)24.52%
Revenue NY rev (1m)1.04%
Revenue NY rev (3m)3.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.62
P/FCF N/A
P/OCF N/A
P/B 2.43
P/tB 2.43
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)-2.65
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0.67
BVpS3.21
TBVpS3.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.42%
ROE -47.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.48%
FCFM N/A
ROA(3y)-32.93%
ROA(5y)-45.22%
ROE(3y)-54.78%
ROE(5y)-218.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.68%
GM growth 5YN/A
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 383.4%
Cap/Sales 9.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.5
Quick Ratio 5.45
Altman-Z -0.34
F-Score4
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)281.39%
Cap/Depr(5y)173.17%
Cap/Sales(3y)4.4%
Cap/Sales(5y)3.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.64%
EPS Next Y-26.2%
EPS Next 2Y-20.3%
EPS Next 3Y-17.61%
EPS Next 5Y19.35%
Revenue 1Y (TTM)7.51%
Revenue growth 3Y10.14%
Revenue growth 5Y73.11%
Sales Q2Q%-30.77%
Revenue Next Year6.2%
Revenue Next 2Y-33.32%
Revenue Next 3Y-40.27%
Revenue Next 5Y45.97%
EBIT growth 1Y-43.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year129.6%
EBIT Next 3Y21.59%
EBIT Next 5YN/A
FCF growth 1Y-67.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.25%
OCF growth 3YN/A
OCF growth 5YN/A